AUTHORS
Zhouning Lin, Luo Wang2, Shuyang Wang, MD3, Mingming Zhang, PhD4, Shan Fu5, Jingjing Feng6, Guoqing Wei7, Alex H. Zhang, Dr.8, He Huang, PhD9, Yongxian HU, MD10
AFFILIATIONS
1 Bone Marrow Transplantation Center, First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
2 Bone Marrow Transplantation Center, First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
3 Bone Marrow Transplantation Center, First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
4 Bone Marrow Transplantation Center, First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
5 Bone Marrow Transplantation Center, First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
6 Bone Marrow Transplantation Center, First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
7 Bone Marrow Transplantation Center, First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
8 Shanghai YaKe Biotechnology Ltd., Shanghai, China
9 Bone Marrow Transplantation Center, First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
10 Bone Marrow Transplantation Center, First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
ABSTRACT
Background
B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T-cell therapy has shown substantial activity in patients with relapsed/refractory multiple myeloma (R/R MM). However, disease progression remains a major clinical challenge. Post-progression disease patterns and outcomes after salvage therapy have not been well described, particularly in patients with extramedullary disease (EMD).
Methods
We retrospectively included 141 patients with R/R MM who received BCMA-directed CAR T-cell therapy between July 2018 and September 2023. Patients were classified according to baseline disease involvement as EMD, paraskeletal disease (PSD), or bone marrow-only disease (BM-only). Among patients who achieved a response after CAR T-cell therapy and subsequently developed disease progression, progression phenotype, first salvage treatment, post-progression progression-free survival (PFS2), and post-progression overall survival (OS2) were analyzed.
Results
Among 141 patients, 36, 29, and 76 had baseline EMD, PSD, and BM-only disease, respectively. Median PFS and OS for the overall cohort were 14.4 and 43.2 months. Median PFS was 7.6, 14.4, and 26.0 months in the EMD, PSD, and BM-only groups, respectively (P<0.001), and median OS was 16.5, 49.2, and 55.5 months, respectively (P<0.001).
Overall, 94 patients developed disease progression after an initial response. The median time from CAR T-cell infusion to progression was 12.4 months. Progression phenotype was evaluable in 82 patients. At progression, 42, 30, and 10 patients had EMD, PSD, and BM-only progression, respectively. Median PFS2 was 3.3, 4.5, and 16.4 months in these groups (P=0.041), and median OS2 was 8.8 months, 27.1 months, and not reached, respectively (P=0.0012).
Among patients with progression, 72 received active first salvage therapy, 6 received palliative/supportive care, and subsequent treatment information was unavailable in 16. First salvage therapy included chemotherapy in 16 patients, novel/targeted therapy in 27, second CAR T-cell therapy in 24, radiotherapy/local therapy in 3, and hematopoietic stem cell transplantation in 2.
Median PFS2 was 3.1, 3.7, and 8.3 months in the chemotherapy, novel/targeted therapy, and second CAR T-cell therapy groups, respectively (P=0.023). Median OS2 was 5.7, 7.2, and 48.2 months, respectively (P<0.001).
Among patients with EMD progression, 31 received one of the three major first salvage approaches. Chemotherapy, novel/targeted therapy, and second CAR T-cell therapy were used in 12, 10, and 9 patients, respectively. Median PFS2 was 3.4, 2.8, and 6.1 months (P=0.080), and median OS2 was 9.6, 5.2, and 20.1 months, respectively (P=0.101).
Conclusions
Patients who progressed after BCMA-directed CAR T-cell therapy had poor outcomes, particularly those with EMD progression. Second CAR T-cell therapy was associated with longer PFS2 and OS2 in the overall progression cohort, supporting cellular therapy sequencing as a potential salvage strategy after post-CAR T-cell relapse. Further studies are needed to define its role in patients with EMD progression.
DISCLOSURES
Zhouning Lin: No relevant conflicts of interest to declare.